Shanghai-based TYK Medicines (HKG: 2410) has successfully completed a Series D financing round, raising nearly RMB 200 million (approximately USD 28 million). The round was led by Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553), with additional investments from CICC Capital, Changxing Financial Holding, and the Huzhou Talent Fund.
Founded in 2017, TYK Medicines operates a 30,000 square meter research and development center in Zhejiang, with its headquarters in Shanghai and a small-molecule screening platform located in Zhengzhou.
The company’s product pipeline features small-molecule anti-tumor drugs with best-in-class and first-in-class potential, including TY-9591, TY-302, and TY-2136b, all of which have entered clinical trials. Notably, TY-2136b received orphan drug designation (ODD) from the U.S. FDA in September. Additionally, compounds targeting RET, CDK7, CDK2/4/6, and Exon20 have completed Investigational New Drug (IND) filings in both the United States and China.
Recently, TYK Medicines has expanded its focus to the central nervous system (CNS) sector, with plans to secure its first IND approval in this area.- Flcube.com
